Register for Upcoming Webinar on DEC. 8 @ 11AM

2023年中国药监局NMPA蓝皮书已发布:

The New Landscape of China Clinical Evaluation: Diversified Pathways to Expedite your Market Approval (Part II)

  • 版本
  • 下载 38
  • 文件大小 0.00 KB
  • 文件计数 1
  • 创建日期 28 3 月, 2024
  • 最后更新 13 5 月, 2024

The New Landscape of China Clinical Evaluation: Diversified Pathways to Expedite your Market Approval (Part II)

Struggling to navigate the intricacies of clinical trial implementation in China? Part II of our webinar series delves deeper into the practical aspects of conducting clinical trials in China for successful NMPA submissions.
Join us as we dissect the critical elements of China's clinical trial framework, focusing on the China GCP, administrative requirements, implementation strategies, regulations about Human Genetic Resources.
* Explore the clinical evaluation requirement for product registration in China
* Learn about the China GCP and clinical trial requirements
* Learn about the clinical trial implementation
* Explore the regulations about Human Genetic Resources related to implementation of clinical trials
* Understand the role of RWE in clinical evidence to support product registration.

Attached Files

文件动作
tsfyjIkfSyYDownload